NMD Pharma presents preclinical data highlighting increased innervation of skeletal muscle with ClC-1 ion channel inhibition treatment in neuromuscular disease model
Company presented clinical and preclinical data at the MDA Conference last week…
ExoPTEN Preclinical Study Demonstrates Significant Potential for Enhancing Motor Function, Blood Flow, and Spinal Cord Injury Recovery
TORONTO and HAIFA, Israel, March 14, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic…
Orion and Aiforia extend collaboration to preclinical study evaluations
March 05, 2025 02:00 ET | Source: Orion Oyj ORION CORPORATION PRESS…
Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
REDWOOD CITY, Calif., March 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc.…
Derm-Biomes DB-007-5 is highly effective at treating atopic dermatitis and reducing itch in preclinical study, outperforming the current leading topical AD drug
VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc,…
Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Society of Toxicology Meeting
Advanced platforms for CROs, pharmaceutical and biotech companies seeking to enhance productivity…
IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference
February 23, 2025 12:07 ET | Source: IO Biotech • Findings support…
Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies
Cayman Islands, January 15, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion”…
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
This is the second asset Menarini Group has inlicensed from Insilico Medicine…
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
This is the second asset Menarini Group has inlicensed from Insilico Medicine…